Novo Nordisk's shares dropped significantly after its late-stage heart drug ziltivekimab failed to reduce major adverse cardiovascular events in a trial. This marks another setback for the Danish drugmaker, impacting investor confidence in its pipeline.
Novo Nordisk faces a lawsuit from shareholders alleging misleading statements about its obesity drug CagriSema's clinical trial, leading to a significant market value drop. A federal judge has allowed parts of the lawsuit to proceed.
Danish pharmaceutical giant Novo Nordisk is suing US-based Eli Lilly in a New Jersey court for "false and misleading" advertisements. Novo Nordisk alleges Eli Lilly used "outdated studies" to compare GLP-1 agonist drugs like Wegovy and Ozempic to Mounjaro and Zepbound, causing confusion.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Novo Nordisk ha demandado a Eli Lilly en EE.UU. por presunta publicidad engañosa, alegando que Lilly compara sus tratamientos para la obesidad y diabetes con dosis antiguas de Novo Nordisk para mostrar resultados superiores. La disputa se da en la carrera por liderar el creciente mercado de fármacos contra la obesidad.
Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.
Novo Nordisk has filed a lawsuit against Eli Lilly in a U.S. court, alleging that Lilly's advertising campaigns for its obesity and diabetes drugs, Zepbound and Mounjaro, mislead consumers by using outdated clinical trials to compare efficacy against Novo's rival injections, Wegovy and Ozempic.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.
Novo Nordisk's weight-loss drugs Wegovy and Ozempic are seeing steady sales growth in India, outpacing generic versions. This comes as the frenzy for Indian generics wanes amid a crowded market, with innovators maintaining a steadier growth trajectory.
The once-a-day Wegovy weight-loss pill, containing semaglutide, is now available in UK high street and online pharmacies for private prescription. It is not yet available on the NHS. The pill offers a needle-free alternative to the jab but requires specific administration on an empty stomach.
Medicare is launching the Bridge demonstration program to cover GLP-1 obesity drugs for eligible beneficiaries with a $50 monthly copay, a first for the program. This temporary initiative, set to expire in 2027, could unlock millions of new patients for Novo Nordisk and Eli Lilly, but raises concerns about healthcare system strain and long-term patient access.
O Ministério da Saúde anunciou um estudo para avaliar o uso da semaglutida no SUS. A substância, usada no tratamento de diabetes e obesidade, pode reduzir o apetite e levar à perda de peso. A proposta visa superar a barreira de preço, com a Novo Nordisk oferecendo um desconto de 59%.
Cyber extortion group FulcrumSec claims to have stolen over 1TB of sensitive data from Novo Nordisk, including source code, drug information, and clinical trial data. The group allegedly demanded $25 million, which Novo Nordisk reportedly refused to pay. FulcrumSec is now reportedly exploring selling the stolen data.
Die Hackergruppe FulcrumSec fordert 25 Millionen Dollar Lösegeld vom Pharmakonzern Novo Nordisk, nachdem sie über ein Terabyte an Daten erbeutet hat. Das Unternehmen lehnte die Zahlung ab. Die Hacker drohen nun mit der Veröffentlichung oder dem Verkauf der gestohlenen Daten, darunter sensible Informationen zu Medikamenten und KI-Modellen.
Die Hackergruppe FulcrumSec fordert 25 Millionen Dollar Lösegeld vom Pharmakonzern Novo Nordisk, nachdem sie über ein Terabyte an Daten erbeutet hat. Das Unternehmen verweigert die Zahlung, und die Hacker drohen mit der Veröffentlichung oder dem Verkauf der gestohlenen Informationen, darunter sensible Medikamentendaten und KI-Modelle.
Die Erpressergruppe FulcrumSec behauptet, Novo Nordisk habe eine Lösegeldzahlung von 25 Mio. USD verweigert, nachdem sie über ein Terabyte an Daten gestohlen hatten. Die Hacker drohen nun mit dem Verkauf der Daten, ziehen aber eine kostenlose Veröffentlichung vor, um andere Unternehmen abzuschrecken.
Cyberkriminelle der Gruppe FulcrumSec behaupten, über ein Terabyte an Daten von Novo Nordisk gestohlen zu haben, darunter Quellcodes und vertrauliche Medikamenteninformationen. Das Unternehmen bestätigte einen IT-Sicherheitsvorfall und verweigert eine Lösegeldzahlung von 25 Millionen Dollar.
Grupo hacker FulcrumSec alega ter roubado mais de 700 mil arquivos da Novo Nordisk, incluindo dados de pacientes e funcionários, e ameaça vender as informações após não conseguir extorquir US$ 25 milhões da empresa.
A EMS lançou sua caneta de semaglutida, Ozivy, nas farmácias brasileiras. O medicamento, primeiro nacional após a queda da patente, tem preço inicial de R$ 452 e visa controlar o nível de açúcar no sangue.
Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.
The UK has approved a pill version of the weight-loss drug Wegovy, manufactured by Novo Nordisk. This once-daily tablet, containing semaglutide, mimics a natural hormone to suppress appetite and slow digestion. While available via prescription from pharmacies soon, its NHS availability is pending expert assessment.
A pill version of the weight-loss drug Wegovy has been approved in the UK by the MHRA. Manufacturer Novo Nordisk states the once-daily tablet offers convenience over weekly injections and doesn't require refrigeration. Its availability on the NHS is pending expert assessment.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the US. The drug, approved for weight management and cardiovascular risk reduction, faces increasing competition in the growing obesity drug market.
